EuroGentest: DNA-based testing for heritable disorders in Europe

Community Genetics

Volumn 11, Issue 2, 2008, Pages 75-120

  Javaher, Poupak ^a   Kääriäinen, Helena ^c,d   Kristoffersson, Ulf ^e   Nippert, Irmgard ^b   Sequeiros, Jorge ^f   Zimmern, Ron ^g   Schmidtke, Jörg ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY OF TURKU   (Finland)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF PORTO   (Portugal)

^g PHG FOUNDATION   (United Kingdom)

Author keywords

Analytical validity; Carrier status; Clinical utility; Clinical validity; Eligibility criteria; Evaluation; Genetic screening; Genetic testing; Predictive testing; Reproductive choice

Indexed keywords

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CZECH REPUBLIC; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA DETERMINATION; ECONOMIC EVALUATION; EUROPE; FINLAND; FRANCE; GENETIC DISORDER; GENETIC HETEROGENEITY; GENETIC SCREENING; GERMANY; HEALTH CARE ACCESS; HEALTH CARE FINANCING; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HEALTH SURVEY; HETEROZYGOTE; HUMAN; INTERNET; ITALY; LITHUANIA; MEDICAL SOCIETY; MONTENEGRO (REPUBLIC); OUTCOMES RESEARCH; PORTUGAL; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROFESSIONAL STANDARD; REVIEW; SERBIA; SPAIN; SWEDEN; UNITED KINGDOM; VALIDATION PROCESS;

COST-BENEFIT ANALYSIS; EUROPE; GENETIC COUNSELING; GENETIC DISEASES, INBORN; GENETIC SCREENING; HEALTH POLICY; HEALTH SERVICES RESEARCH; HUMANS; PRENATAL DIAGNOSIS; PUBLIC HEALTH;

EID: 38349193707     PISSN: 14222795     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111984     Document Type: Review

References (89)

1. Harris R (ed): Genetic services in Europe: a comparative study of 31 countries by the Concerted Action on Genetic Services in Europe. Eur J Hum Genet 1997;5(suppl 2):1-220.
2. Ibarreta D, Elles R, Cassiman JJ, Rodriguez-Cerezo E, Dequeker E: Towards quality assurance and harmonization of genetic testing services in the European Union. Nat Biotechnol 2004;22:1230-1235.
3. Schmidtke J, Pabst B, Nippert I: DNA-based testing is rising steeply in a national health care system with open access to services - a survey of genetic test utilisation in Germany 1996-2002. Genet Testing 2005;9:80-84.
4. Cassiman JJ: Research network: EuroGentest - a European Network of Excellence aimed at harmonizing genetic testing services. Eur J Hum Genet 2005;13:1103-1105.
5. UKGTN: http://www.ukgtn.nhs.uk/gtn/UKGTN-information/dossier.html
6. OECD pilot survey on Molecular Genetic Testing Laboratory Practices, 2002 (Jorge Sequeiros, pers commun).
7. EuroGentest: http://www.urogentest.org
8. Sequeiros J, Guimarães B: Definitions of genetic testing, unpublished data.
9. Kroese M, Zimmern R, Sanderson S: Genetic tests and their evaluation: can we answer the key questions? Genet Med 2004;6:475-480.
10. Council of Europe: http://www.coe.int/
11. Holtzman NA, Watson MS: US Task Force on Genetic Testing in the United States: Final report. Promoting safe and effective genetic testing in the United States. Bethesda, National Human Genome Research Institute, 1997, pp 1-82.
12. Sanderson S, Zimmern R, Kroese M, Higgins J, Patch C, Emery J: How can the evaluation of genetic tests be enhanced? Lessons learned from the ACCE framework and evaluating genetic tests in the United Kingdom. Genet Med 2005;7:495-500.
13. Ibarreta D, Bock AK, Klein C, Rodriguez-Cerezo E: Towards quality assurance and harmonisation of genetic testing services in the EU. Report EUR 20977 EN, JRC-IPTS and JRC-IRMM. Brussels, European Communities, 2003.
14. OMIM: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db = OMIM.
15. Eurodis: http//www.eurordis.org.
16. Skirton H: Parental experience of a pediatric genetic referral. MCN Am J Matern Child Nurs 2006;31:178-184.
17. Skirton H: The client's perspective of genetic counselling - a grounded theory study. J Genet Couns 2001;10:311-329.
18. American College of Medical genetics. http://www.mchb.hrsa.gov.
19. Wilson JM: Principles and Practice of Screening for Diseases. Geneva, World Health Organization, 1968.
20. Dixon A, Mossialos E (eds): Health care systems in eight countries: trends and challenges. Report commissioned by the Health Trends Review, HM Treasury. London, European Observatory on Health Care Systems, 2002.
21. Anell A, Willis M: International comparison of health care systems using resource profiles. Bull World Health Organ 2000;78:770-777.
22. Grimmeisen S, Rothgang H: The changing role of the state in Europe's health care systems. Second Annual ESPAnet Conference, University of Oxford, September 2004.
23. Penchaszadeh VB: Delivery of Genetic Services in Developing Countries. New York, Oxford University Press, 2000.
24. Bittles AH, Savithri HS, Appaji Rao N: Community genetics in developing countries. Community Genet 2002;5:151-152.
25. Van Weely S, Leufkens HGM: Orphan diseases; in Kaplan W, Laing R (eds): Priority Medicines for Europe and the World - A Public Health Approach to Innovation. Geneva, World Health Organisation, 2004, pp 95-100.
26. Burke W, Zimmern RL: Ensuring the appropriate use of genetic tests. Nat Rev Genet 2004;5:955-959.
27. Krawczak M, Cooper DN, Schmidtke J: Estimating the efficacy and efficiency of cascade genetic screening. Am J Hum Genet 2001;69:361-370.
28. Morris JK, Law MR, Wald NJ: Is cascade testing a sensible method of screening a population for autosomal recessive disorders? Am J Med Genet 2004;128A:271-275.
29. Krawczak M, Caliebe A, Croucher PJP, Schmidtke J: On the testing load incurred by carrier screening for Mendelian disorders. In press.
30. Vogel F, Motulsky A: Human Genetics. Problems and Approaches, ed 3. Berlin, Springer, 1997.
31. Drummond MF, Manca A, Sculpher MJ: Increasing the generalisability of economic evaluations: recommendations for the design, analysis, and reporting of studies. Int J Technol Assess Health Care 2005;21:165-171.
32. Torrance N, Mollison J, Wordsworth S, Gray J, Miedzybrodzka Z, Haites N, Grant A, Campbell M, Watson MS, Clarke A, Wilson B: Genetic nurse counsellors can be an acceptable and cost-effective alternative to clinical geneticists for breast cancer risk genetic counselling. Evidence from two parallel randomised controlled equivalence trials. Br J Cancer 2006;95:435-444.
33. Briggs AH, O'Brien BJ: The death of cost-minimization analysis? Health Econ 2001;10:179-184.
34. Williams A: Economics of coronary artery bypass grafting. Br Med J (Clin Res Ed) 1985;291:326-329.
35. Drummond M, O'Brien B, Stoddard G, Torrance G: Methods for the Economic Evaluation of Health Care Programmes. Oxford, Oxford University Press, 1997.
36. Ryan M, Gerard K: Using discrete choice experiments in health economics: moving forward; in Scott A, Maynard A, Elliott RF (eds): Advances in Health Economics. Chichester, Wiley, 2003.
37. Sculpher M, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, Davies LM, Eastwood A: Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess 2004;8:1-206.
38. Welte R, Feenstra T, Jager H, Leidl R: A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 2004;22:857-876.
39. Schöffski O: Genetic testing and the health care system. Eur J Health Econo 2002;2:73-76.
40. Evers S, Goossens M, de Vet H, van Tulder M, Ament A: Criteria list for assessment of methodological quality of economic evaluations: consensus on Health Economic Criteria. Int J Technol Assess Health Care 2005;21:240-245.
41. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S: Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 2006;24:355-371.
42. Zika E, Gurwitz D, Ibarreta D: Pharmacogenetics and Pharmacogenomics: State-of-the-art and potential socio-economic impacts in the EU. Report EUR 22214 EN. Brussels, European Commission, Joint Research Centre, Institute for Prospective Technological Studies, 2006. www.jrc.es/home/pages/detail.cfm?prs= 1387.
43. Vernon JA, Johnson SJ, Hughen WK, Trujillo A: Economic and developmental considerations for pharmacogenomic technology. Pharmacoeconomics 2006;24:335-343.
44. Phillips KA, Van Bebber SL: A systematic review of cost-effectiveness analysis of pharmacogenomic interventions. Pharmacogenomics 2004;5:1139-1149.
45. Rogowski W: Current impact of gene technology on healthcare. A map of economic assessments. Health Policy 2007;80:340-357.
46. Rogowski W: Genetic screening by DNA technology. A systematic review of health economic evidence. Int J Technol Assess Health Care 2006;22:327-337.
47. Jarrett J, Mugford M. Genetic health technology in economic evaluation: A critical review. Applied Health Econ Health Policy 2006;5:27-35.
48. ACCE: http://www.cdc.gov/genomics/gtesting/ACCE.htm.
49. CDC: http://www.cdc.gov/.
50. EGAPP: http://www.cdc.gov/genomics/gtesting/EGAPP/info.htm.
51. Gene Dossier, UKGTN: http://www.ukgtn.nhs.uk/gtn/UKGTN-information/ dossier.html.
52. Cangènetest: http://www.cangenetest.org/fr/contacts.html.
53. HiT Czech Republic, 2004: http://www.euro.who.int/Document/E86823sum.pdf.
54. Macek M: Questionnaire to collect information on different areas of genetic testing from the European member states, unpubl data.
55. Pan American Health Organization: http://www.paho.org/English/DD/AIS/ cp_218.htm.
56. HiT Finland, 2002: http://www.euro.who.int/Document/Obs/FINsum112002.pdf.
57. Kääriäinen H: Questionnaire to collect information on different areas of genetic testing from the European member states, unpubl data.
58. Matthiessen-Guyader L (ed): Survey on National Legislation and Activities in the Field of Genetic Testing in EU Member States. Brussels, European Commission, Research Directorate-General, 2005. http://ec.europa.eu/research/ biosociety/pdf/bioethics-survey-test2106.pdf.
59. Autti-Rämö, MäkeläM, Sintonen H, Koskinen H, Laajalahti L, Halila R, Kääriäinen H, Lapatto R, Näntö-Salonen K, Pulkki K, Renlund M, Salo M, Tyni T: Expanding screening for rare metabolic disease in the newborn: an analysis of costs, effect and ethical consequences for decision making in Finland. Acta Paediatr 2005;94:1126-1136.
60. HiT France, 2004: http://www.euro.who.int/document/e83126sum.pdf.
61. Claustres M: Questionnaire to collect information on different areas of genetic testing from the European member states, unpubl data.
62. Nippert I, Horst J, Schmidtke J: Genetic services in Germany. Eur J Hum Genet 1997;5(suppl 2):81-88.
63. HiT Germany, 2004: http://www.euro.who.int/Document/E85472sum.pdf.
64. European Observatory on Health Care Systems: http://www.euro.who.int/ observatory.
65. Nippert I: Provision of prenatal genetic diagnosis in the Federal Republic of Germany. Birth Defects Orig Artic Ser 1992;28:68-81.
66. Bundesärztekammer, Weiterbildungsordnung: http://www. bundesaerztekammer.de/page.asp?his = 1.128.
67. BVDH: http://www.bvdh.de/.
68. Gfh: http://www.gfhev.de/.
69. Gemeinsamer Bundesausschuss: http://www.g-ba.de/.
70. HiT Italy, 2001: http://www.euro.who.int/Document/E73096sum.pdf.
71. Dallapiccola B, Torrente I, Morena A, Dagna-Bricarelli F, Mingarelli R: Genetic testing in Italy, year 2004. Eur J Hum Genet 2006;14:911-916.
72. Dagna Bricarelli F: Questionnaire to collect information on different areas of genetic testing from the European member states, unpubl data.
73. HiT Lithuania, 2000: http://www.euro.who.int/Document/E69920.pdf.
74. Kučinskas V: Questionnaire to collect information on different areas of genetic testing from the European member states, unpubl data.
75. HiT Portugal, 2004: http://www.euro.who.int/document/E82937sum.pdf.
76. Sequeiros J: Questionnaire to collect information on different areas of genetic testing from the European member states, unpubl data.
77. OECD Survey on Quality Assurance and Proficiency Testing Schemes for Molecular Genetic Testing in 18 OECD Countries. Report from the Working Party on Biotechnology, Directorate for Science, Technology and Industry, Committee for Scientific and Technological Policy, 24 May 2004.
78. Radojkovic D, Brankovic S: Questionnaire to collect information on different areas of genetic testing from the European member states, unpubl data.
79. HiT Spain, 2002: http://www.euro.who.int/document/Obs/SPAsum112002.pdf.
80. Ramos F: Questionnaire to collect information on different areas of genetic testing from the European member states, unpubl data.
81. Antiñolo G, Pérez Jurado L: Questionnaire to collect information on different areas of genetic testing from the European member states, unpubl data.
82. HiT Sweden, 2002: http://www.euro.who.int/document/Obs/SWEsum112002.pdf.
83. Kristoffersson U: Questionnaire to collect information on different areas of genetic testing from the European member states, unpubl data.
84. Swedish Society of Human Genetics: http://www3.svls.se/sektioner/mg/.
85. HiT UK, 1999: http://www.euro.who.int/document/e68283.pdf.
86. Donnai D, Elles R: Integrated regional genetic services: current and future provision. BMJ 2001;322:1048-1052.
87. Kroese M, Zimmern R: Questionnaire to collect information on different areas of genetic testing from the European member states, unpubl data.
88. Mossialos E, Dixon A, Figueras J, Kutzin J (eds): Funding Health Care: Options for Europe. European Observatory on Health Care Systems Series. Buckingham, Open University Press, 2002.
89. Centres for Disease Control and Prevention: http://www.cdc.gov/.